8 July 2026
Through opnMe, our freely available preclinical molecules have enabled scientists worldwide to test and validate their research hypotheses, contributing to more than 250 independent, peer‑reviewed publications to date.
To further enable systematic screening and profiling approaches for the validation of novel, disease‑relevant biological hypotheses, we made the entire opnMe molecule library available for a limited time as a single, ready‑to‑screen microtiter plate.
To access this valuable research tool, we invited scientists to address the following question with a research proposal:
How would you leverage the entire opnMe molecule library to address new biological questions in the context of human disease as part of screening and profiling activities?
All research proposals were evaluated by an internal review team, which selected 26 proposals as winners. The selected scientists will receive the opnMe compound library to pursue their research independently. Intellectual ownership of all resulting data will remain with the submitting scientists, who are encouraged to publish their findings in high‑impact, peer‑reviewed journals.
Subscribe to our newsletter to stay updated as we add new molecules to opnMe.com.
About opnMe:
opnMe.com, the open science portal of Boehringer Ingelheim, fosters science and collaboration initiatives in areas of high unmet medical need. Our molecules are provided to the scientific community either free of charge as “Molecules to Order” or applied for via scientific research submissions as “Molecules for Collaboration”. With our “opn2EXPERTS” and “techMATCH” calls, we enlist scientific advice on key scientific topics to fuel further drug discovery and deliver novel solutions that benefit unmet patient needs. Our "opn2TALENTS" postdoc grants at one of our research sites offer opportunities for high-level talents to propose innovative approaches for precisely defined scientific questions.